Evaluation of Serum Resistin, Visfatin, and Chemerin Levels in Patients with Lung Cancer and Chronic Obstructive Pulmonary Disease

Basit Öğe Kaydı
dc.contributor.authorGoktepe, Mustafa
dc.contributor.authorKorkmaz, Celalettin
dc.contributor.authorZamani, Adil
dc.contributor.authorDemirbas, Soner
dc.contributor.authorKilinc, Ibrahim
dc.date.accessioned2024-02-23T14:41:19Z
dc.date.available2024-02-23T14:41:19Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractOBJECTIVES: Cachexia is an important problem in lung cancer and chronic obstructive pulmonary disease (COPD). Some studies report an association between adipokines and cachexia. Our study aimed to investigate the association of three novel adipokines, resistin, visfatin, and chemerin, with lung cancer and COPD. MATERIALS AND METHODS: 30 patients with non-smallcell lung cancer, 30 patients with COPD, and 30 healthy volunteers were included in the study. Statistically significant weight loss was found in COPD and lung cancer groups compared with that in the control group (p<0.001). Among the biomarkers, only resistin levels were significantly higher in patients with cachexia than in patients without weight loss in all groups (p=0.006). Resistin level was significantly higher in patients with COPD (p=0.002). Visfatin level was significantly higher in the control group (p=0.001). We found that a higher biomass exposure resulted in a significant increase and decrease in resistin (p=0.007) and visfatin levels (p=0.001), respectively, in the patient groups. For all groups, no statistically significant relationship was found between chemerin levels and weight loss or other variables. RESULTS: No significant relationship was found between the biomarkers and lung cancer type, tumor stage, lymph node stage, and metastasis stage. There was no relationship between the biomarkers by tumor, node, and metastasis and COPD stages (p>0.05). We observed no findings strong enough to support the use of these molecules as markers of disease stage or cachexia. CONCLUSION: Resistin, visfatin, and chemerin cannot be used as potential biomarkers for lung cancer or COPD or for disease stage or cachexia.en_US
dc.description.sponsorshipNecmettin Erbakan University Scientific Research Projects Coordination [141518016]en_US
dc.description.sponsorshipThis project was supported by Necmettin Erbakan University Scientific Research Projects Coordination. (project number: 141518016)en_US
dc.identifier.doi10.5152/TurkThoracJ.2019.19001
dc.identifier.endpage173en_US
dc.identifier.issn2149-2530
dc.identifier.issue3en_US
dc.identifier.pmid32584233en_US
dc.identifier.scopus2-s2.0-85086944185en_US
dc.identifier.startpage169en_US
dc.identifier.urihttps://doi.org/10.5152/TurkThoracJ.2019.19001
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16809
dc.identifier.volume21en_US
dc.identifier.wosWOS:000540904400006en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Thoracic Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdipokinesen_US
dc.subjectCachexiaen_US
dc.subjectChronic Obstructive Pulmonary Diseaseen_US
dc.subjectLung Canceren_US
dc.titleEvaluation of Serum Resistin, Visfatin, and Chemerin Levels in Patients with Lung Cancer and Chronic Obstructive Pulmonary Diseaseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu